CERSCerus Corp.
Earnings Recap
• Reported GAAP EPS of -$0.01 up 75.00% YoY • Reported revenue of $59.89M up 22.60% YoY • Cerus now expects full-year 2026 product revenue between $227 million and $231 million, a 10% to 12% growth from 2025, including $22 million to $24 million in INTERCEPT Fibrinogen Complex revenue guidance.
Bullish
Cerus achieved strong revenue growth, driven by increased INTERCEPT Fibrinogen Complex demand and a new supply agreement. The company also significantly improved profitability, reducing net loss and increasing adjusted EBITDA.
Bearish
Cerus' product gross margin decreased due to prior year benefits and current inflationary pressures, while cash used in operations increased. The company also faces significant regulatory approval and market acceptance risks for its products.